Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
a12FwtRZdqPcNqKu
